Larimar Therapeutics (Larimar Therapeutics) Cash Flow from Financing : $162.15 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Larimar Therapeutics Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Mar. 2024, Larimar Therapeutics received $162.15 Mil more from issuing new shares than it paid to buy back shares. It received $0.00 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.00 Mil on other financial activities. In all, Larimar Therapeutics earned $162.15 Mil on financial activities for the three months ended in Mar. 2024.

Larimar Therapeutics Cash Flow from Financing Historical Data

The historical data trend for Larimar Therapeutics's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Larimar Therapeutics Cash Flow from Financing Chart

Larimar Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash Flow from Financing

19.40

93.59

19.89

75.26

0.03

Larimar Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash Flow from Financing	Get a 7-Day Free Trial															-	-	-	-	162.15

Larimar Therapeutics Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Larimar Therapeutics's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

	Cash Flow from Financing		(A: Dec. 2023 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0	+	0	+	0	+	0	+	0	+	0
=	0.00

Larimar Therapeutics's Cash from Financing for the quarter that ended in Mar. 2024 is:

	Cash Flow from Financing		(Q: Mar. 2024 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	162.151	+	0	+	0	+	0	+	0	+	0
=	162.15

Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $162.15 Mil.

Larimar Therapeutics (NAS:LRMR) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Larimar Therapeutics's issuance of stock for the three months ended in Mar. 2024 was $162.15 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Larimar Therapeutics's repurchase of stock for the three months ended in Mar. 2024 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Larimar Therapeutics's net issuance of debt for the three months ended in Mar. 2024 was $0.00 Mil. Larimar Therapeutics received $0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Larimar Therapeutics's net issuance of preferred for the three months ended in Mar. 2024 was $0.00 Mil. Larimar Therapeutics paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Larimar Therapeutics's cash flow for dividends for the three months ended in Mar. 2024 was $0.00 Mil. Larimar Therapeutics received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Larimar Therapeutics's other financing for the three months ended in Mar. 2024 was $0.00 Mil. Larimar Therapeutics received $0.00 Mil on other financial activities.

Larimar Therapeutics Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Larimar Therapeutics's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Larimar Therapeutics (Larimar Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Larimar Therapeutics Inc (NAS:LRMR) » Definitions » Cash Flow from Financing

Comparable Companies

Traded in Other Exchanges

ZA71:Germany

Address

Three Bala Plaza East, Suite 506, Bala Cynwyd, PA, USA, 19004

Website

https://www.larimartx.com

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Executives

Gopi Shankar	officer: Chief Development Officer	C/O LARIMAR THERAPEUTICS, INC., THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD PA 19004
Jeffrey W Sherman	director	C/O IDM PHARMA, INC., 9 PARKER, SUITE 100, IRVINE CA 92618
Russell Clayton	officer: Chief Medical Officer	2600 KELLY RD, WARRINGTON PA 18976
Carole Ben-maimon	director, officer: President and CEO	C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544
Michael Celano	officer: Chief Financial Officer	220 EAST FIRST STREET, BETHLEHEM PA 18015
Joseph Truitt	director	C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Thomas Edward Hamilton	director	211 STUYVESANT AVE, RYE NY 10580
James E Flynn	10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Jonathan S Leff	director	C/O DEERFIELD MANAGEMENT COMPANY, L.P, 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Mgmt Hif, L.p.	director, 10 percent owner, other: Director by Deputization	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Chondrial Therapeutics Holdings, Llc	10 percent owner	150 MONUMENT ROAD, SUITE 207, BALA CYNWYD PA 19004
Deerfield Mgmt Iv, L.p.	director, 10 percent owner, other: Director by Deputization	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Private Design Fund Iv, L.p.	director, 10 percent owner, other: Director by Deputization	780 THIRD AVENUE 37TH FLOOR, NEW YORK NY 10017
Deerfield Healthcare Innovations Fund, L.p.	director, 10 percent owner, other: Director by Deputization	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Mgmt Iii, L.p.	director, 10 percent owner, other: Director by Deputization	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017